Home » Barr Confirms Patent Challenge of Ritalin LA
Barr Confirms Patent Challenge of Ritalin LA
Barr Laboratories is challenging the patents listed by Novartis Pharmaceuticals in connection with its Ritalin LA extended-release capsules, 10, 20, 30 and 40 mg.
Barr filed its abbreviated new drug application containing a Paragraph IV certification for a generic Ritalin LA (methylphenidate hydrochloride) product with the FDA in May and received notification of the application’s acceptance for filing in September.
Celgene and Novartis filed suit Nov. 2 in the U.S. District Court of New Jersey to prevent Barr from proceeding with the commercialization of the product, Barr said.
Ritalin LA extended-release capsules are indicated for the treatment of attention deficit hyperactivity disorder.
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May